Showing results (1811-1820 of 1,827) with videos related to
Sort By:
Pageof 183
Cell Reports. Medicine|July 17, 2024
Preclinical development of a stabilized RH5 virus-like particle vaccine that induces improved antimalarial antibodiesLloyd D W King, David Pulido, Jordan R Barrett, et al.Gastrointestinal Endoscopy|July 24, 2025
Clinical outcomes of endoscopic submucosal dissection for residual neoplasia after incomplete resection of large nonpedunculated colorectal polyps: a large multicenter propensity match study (with video)Ernesto Robalino Gonzaga, Yiyang Zhang, Abdul S Mohammed, et al.Biorxiv : the Preprint Server for Biology|February 9, 2026
A Chemical-Genetic Interaction Matrix Reveals Drug Mechanism and Genetic ArchitectureJasmin Coulombe-Huntington, Thierry Bertomeu, Caroline Huard, et al.Science Translational Medicine|July 12, 2023
Vaccination with Plasmodium vivax Duffy-binding protein inhibits parasite growth during controlled human malaria infectionMimi M Hou, Jordan R Barrett, Yrene Themistocleous, et al.Medrxiv : the Preprint Server for Health Sciences|June 6, 2022
Impact of a blood-stage vaccine on Plasmodium vivax malariaMimi M Hou, Jordan R Barrett, Yrene Themistocleous, et al.Science (New York, N.Y.)|May 13, 2022
Cross-tissue immune cell analysis reveals tissue-specific features in humansC Domínguez Conde, C Xu, L B Jarvis, et al.Cell|July 26, 2024
Analysis of the diverse antigenic landscape of the malaria protein RH5 identifies a potent vaccine-induced human public antibody clonotypeJordan R Barrett, Dimitra Pipini, Nathan D Wright, et al.Journal of Medicinal Chemistry|February 3, 2017
Discovery of a First-in-Class Receptor Interacting Protein 1 (RIP1) Kinase Specific Clinical Candidate (GSK2982772) for the Treatment of Inflammatory DiseasesPhilip A Harris, Scott B Berger, Jae U Jeong, et al.Nature|September 9, 2021
Cells of the human intestinal tract mapped across space and timeRasa Elmentaite, Natsuhiko Kumasaka, Kenny Roberts, et al.The Lancet. Infectious Diseases|June 16, 2024
Blood-stage malaria vaccine candidate RH5.1/Matrix-M in healthy Tanzanian adults and children; an open-label, non-randomised, first-in-human, single-centre, phase 1b trialSarah E Silk, Wilmina F Kalinga, Jo Salkeld, et al.Pageof 183